- 米国企業
- Intellia Therapeutics, Inc.
Intellia Therapeutics, Inc.NTLA
時価総額
$23.5億
PER
| 2016年 12月31日 | 2017年 12月31日 | 2018年 12月31日 | 2019年 12月31日 | 2020年 12月31日 | 2021年 12月31日 | 2022年 12月31日 | |
| Collaboration revenue | - | - | 30 | 43 | 58 | - | 52 |
| Research and development | 32 | 68 | 89 | 108 | 150 | - | 420 |
| General and administrative | 17 | 28 | 32 | 41 | 44 | - | 90 |
| Total operating expenses | 49 | 96 | 121 | 149 | 195 | - | 510 |
| Operating loss | -32 | -70 | -91 | -106 | -137 | - | -458 |
| Interest income | 1 | 2 | 6 | 7 | 2 | - | 9 |
| Loss from equity method investments | - | - | - | - | - | 1 | -11 |
| Change in fair value of contingent consideration | - | - | - | - | - | - | 13 |
| Total other (expense) income, net | - | - | - | - | - | - | -16 |
| Net loss | -32 | -68 | -85 | -100 | -134 | -268 | -474 |
| Net Loss Per Share, Basic | - | - | - | - | - | - | -6.16 |
| Net Loss Per Share, Diluted | - | - | - | - | - | - | -6.16 |
| Unrealized loss on marketable securities | - | - | -0 | 0 | -0 | - | -2 |
| Other comprehensive loss from equity method investment | - | - | - | - | - | - | -3 |
| Comprehensive loss | - | - | -85 | -99 | -134 | - | -479 |